Britta Paschen | VP, Head of Global Evidence and Value Development
Merck KGaA

Britta Paschen, VP, Head of Global Evidence and Value Development, Merck KGaA

Britta Paschen
Healthcare / Global Research & Development / Head of Evidence & Value Development

  • Pharmacist by training (Goethe University, Frankfurt am Main)
Post-graduate Diploma / Master degrees:
  • Economics & Financial Management (Technical University Mannheim),
  • Health Economics (Stockholm School of Economics),
  • Business Administration (London City School), and
  • Health Outcomes Research (Harvard School of Public Health)
After joining Merck KGaA in 1987, Britta Paschen gained comprehensive professional experience in various international managerial and executive positions in the areas Pharmaceutical Production, Quality Assurance, Business Development, Strategic Marketing, Transfer Pricing, Market Access, Operational & Strategic Pricing, and Health Services Research. Assignments abroad comprised, for example, the leadership of a 1-year process validation project in Latin-American production hubs. Britta was involved in Merck’s 51% acquisition of the generics holding Amerpharm, which was sold in 2007, the start up and roll out of Merck’s Oncology Business, and she has built up from scratch the company’s organizational structures and capabilities in Market Access (Pricing & Reimbursement, Health Economics, Health Outcomes & Health Services Research). Currently Britta Paschen is the Head of Global Evidence & Value Development within Merck Healthcare and reports into Global R&D. Put in place in 2014, the function is integral in driving evidence-based value strategy and value demonstration for Merck’s portfolio assets and brands, to maximize HTA and reimbursement opportunities for the benefit of patients.
Britta’s main areas of professional interest comprise healthcare decision making, funding and organization of health services, operational and strategic value based pricing & reimbursement (P&R), health economics, market access, health outcomes research, and health technology assessment (HTA) requirements and proceedings. Within Merck Serono, Britta does closely collaborate with all global R&D platforms and Businesses. She is an organizational member of the HTAi Policy Forum, EFPIA HTA WG, ISPOR, and has a strong reputation and track record as speaker in international congresses and congregations.


Day Two World Pharma Pricing & Market Access EU Congress @ 14:05

Chair’s remarks

back to speakers